Sobi's Doptelet Launch In EU To Drive Transformation
UK Is First EU Market For Commercial Launch
Executive Summary
Sobi is launching the thrombocytopenia drug Doptelet in Europe after acquiring the originator, Dova Pharmaceuticals, and expects to capture significant market share from older products while adding to its business in rare diseases, hematology, and immunology.